ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Sunday, November 13, 2016

9:00AM-11:00AM
Abstract Number: 792
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
9:00AM-11:00AM
Abstract Number: 50
Tai Chi Significantly Modulates Resting State Functional Connectivity of the Cognitive Control Network in Fibromyalgia
Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus
9:00AM-11:00AM
Abstract Number: 864
Takayasu Arteritis Developed over the Age of 40 Has Lower Levels of Interferon Gamma and Interleukin 17 at Disease Onset and Fewer Subsequent Relapses
Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 852
Targeting Fibroblastoid-like Cells By Drug Loaded Engineered Gold Nanoparticles As a Novel Approach for ILD-SSc Treatment
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster I
9:00AM-11:00AM
Abstract Number: 674
Targeting Glandular IL-21-Production in Primary Sjogren′s Syndrome Patients By Immunomodulatory Treatment
Sjögren's Syndrome - Poster I: Translational Science
9:00AM-11:00AM
Abstract Number: 484
Targeting the BTK-JAK Axis in Preclinical Models of Rat Collagen-Induced Arthritis with GS-4059 in Combination with a JAK Inhibitor
Rheumatoid Arthritis – Animal Models - Poster I
9:00AM-11:00AM
Abstract Number: 460
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Rheumatoid Arthritis – Animal Models - Poster I
9:00AM-11:00AM
Abstract Number: 577
TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I
9:00AM-11:00AM
Abstract Number: 439
Temple University Hospital Rheumatology Narcotic Contract
Quality Measures and Quality of Care - Poster I
9:00AM-11:00AM
Abstract Number: 903
Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?
Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 867
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 493
The 2010 ACR/EULAR Criteria Are Not Sufficiently Accurate in the Early Identification of Autoantibody-Negative Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis
9:00AM-11:00AM
Abstract Number: 102
The 2015 American College of Rheumatology (ACR) Workforce Study: A Snapshot of Academic Division Directors
Health Services Research - Poster I
9:00AM-11:00AM
Abstract Number: 136
The 7-Joints Musculoskeletal Ultrasound Score (US7 score) Predicts Therapeutic Change in Patients with Early Rheumatoid Arthritis
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
9:00AM-11:00AM
Abstract Number: 135
The 8-Joint Ultrasound Score Is a Useful Marker for Monitoring Therapeutic Response in Rheumatoid Arthritis
Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies
  • «Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 70
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology